Tincup
Honored Contributor (10K+ posts)
Member # 5829
posted
The Lyme duck pond isn't big enough, I guess. Now they are giving advise on Babesia too... AFTER a patient died.
As always.... too little, too late. ^%#^*^$ ducks!
Clin Infect Dis. 2010 Jan 4. [Epub ahead of print]
Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection. Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, Mittleman A, Aguero-Rosenfeld M, Topal J, Krause PJ.
Divisions of 1Infectious Diseases and 2Hematology/Oncology, Departments of Medicine and 3Pathology, New York Medical College, Valhalla; 4Division of Infectious Diseases, Rockville General Hospital, Rockville, and 5Division of Infectious Diseases, 6Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut.
Background. Babesiosis is an emerging tickborne malaria-like infection principally caused by Babesia microti. This infection typically resolves either spontaneously or after administration of a 7-10-day course of azithromycin plus atovaquone or clindamycin plus quinine.
Although certain highly immunocompromised patients may respond suboptimally to these drug regimens, unlike the situation with malaria there has been no reported evidence that the cause of treatment failure is infection with drug-resistant strains of B. microti.
Methods. Emergence of drug resistance in B. microti was defined as the development of a microbiologic relapse (recurrent parasitemia or a marked increase in parasitemia) in association with both clinical and laboratory abnormalities indicative of active babesiosis in a patient after 28 days of uninterrupted antibabesia drug therapy and while still receiving treatment.
Results. The clinical case histories of 3 highly immunocompromised patients who received a subcurative course of azithromycin-atovaquone associated with the eventual development of resistance to this drug regimen are described.
One of the 3 patients died of complications related to babesiosis.
Conclusions. B. microti may become resistant to azithromycin-atovaquone during the treatment of babesiosis with this combined drug regimen in highly immunocompromised patients.
Although research is needed to determine the optimal therapy for highly immunocompromised patients with babesiosis, reducing the level of immunosuppression when possible would appear to be a desirable strategy.
PMID: 20047477 [PubMed - as supplied by publisher]
posted
Idiots... anyone with half an ounce of common sense would stop and say.. "hmm wonder if we treated it long enough?" You would think doctors learn the life cycle of a red blood cell, but then again you would think doctors took at least one chemistry or nutrition class in med school, yet they don't.
Posts: 499 | From Indiana | Registered: Oct 2007
| IP: Logged |
cactus
Frequent Contributor (1K+ posts)
Member # 7347
posted
What are the insurance companies going to do with this info?
Would hate to see them limiting their coverage of Mepron to 7 - 10 days!!!!
-------------------- �Did you ever stop to think, and forget to start again?� - A.A. Milne Posts: 1987 | From No. VA | Registered: May 2005
| IP: Logged |
seekhelp
Frequent Contributor (5K+ posts)
Member # 15067
posted
Why didn't they contact Dr. S in FL for help? He's the expert, right?
Posts: 7545 | From The 5th Dimension - The Twilight Zone | Registered: Mar 2008
| IP: Logged |
sutherngrl
Frequent Contributor (1K+ posts)
Member # 16270
posted
The insurance companies probably paid them to write this! They both make money by publising this kind of information; and its all about money. Unfortunately it causes many ppl to suffer.
Posts: 4035 | From Mississippi | Registered: Jul 2008
| IP: Logged |
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/
UBBFriend: Email this page to someone!
Printer-friendly view of this topic